RxDoctor Payments Data

Michelle Slavin, APRN

Family · Southington, CTNPI 1619499274

Payments from drug & device makers

$2,198in general payments, 2019–2025

Across 54 payments — averaging $40.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Xeris Pharmaceuticals, Inc.$481
  • Medtronic$324
  • Mannkind Corporation$238
  • Dexcom, Inc.$222
  • Cequr Corporation$214
  • Abbott$197
  • plus $522 from 7 others

What the payments were for

  • Travel & lodging$10%
  • Food & beverage$2,13797%
  • Gifts$593%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,198 in reported general payments places this provider in the 80th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$26,298
Medicare patients
75
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide352$413,689
OzempicSemaglutide183$296,903
Tresiba Flextouch U-200Insulin Degludec93$128,652
TrulicityDulaglutide83$119,710
Synjardy XrEmpagliflozin/Metformin Hcl76$115,710
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog91$110,040
JardianceEmpagliflozin75$96,535
Lyumjev Kwikpen U-100Insulin Lispro-Aabc72$67,271
Lyumjev Kwikpen U-200Insulin Lispro-Aabc14$64,620
Tresiba Flextouch U-100Insulin Degludec81$57,018
Soliqua 100-33Insulin Glargine/Lixisenatide30$52,608
FarxigaDapagliflozin Propanediol41$51,466
Humalog Kwikpen U-200Insulin Lispro25$48,292
Xultophy 100-3.6Insulin Degludec/Liraglutide28$45,811
TradjentaLinagliptin47$42,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog$79$376,564247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,596 family providers in Connecticut.

Other family in Southington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →